Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

PDN Post Market, Multicenter, Prospective, Global Clinical Study

NCT: NCT05301816 · ACTIVE_NOT_RECRUITING

NCT IDNCT05301816
StatusACTIVE_NOT_RECRUITING
Start Date2022-07-05
Completion2028-10
SponsorNevro Corp (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this post-market study is to evaluate the real-world experience of Nevro's Spinal Cord Stimulation (SCS) therapy in patients with chronic, intractable leg pain due to painful diabetic neuropathy (PDN). This is a multicenter, prospective, observational global study, that will partner diabetes management teams with pain physicians to provide an interdisciplinary treatment regimen for PDN patients. Outcomes will be assessed via standardized assessments.

Frequently Asked Questions

What is PDN Post Market, Multicenter, Prospective, Global Clinical Study?

PDN Post Market, Multicenter, Prospective, Global Clinical Study is a clinical trial registered under NCT05301816. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05301816?

The current status of NCT05301816 (PDN Post Market, Multicenter, Prospective, Global Clinical Study) is: ACTIVE_NOT_RECRUITING.

When did PDN Post Market, Multicenter, Prospective, Global Clinical Study start?

PDN Post Market, Multicenter, Prospective, Global Clinical Study started on 2022-07-05.

Related Devices

PMA P130022Stimulator, spinal-cord, totally implanted for pain reliefNevro Corporation K182720Freedom Spinal Cord Stimulator (SCS) SystemStimwave Technologies Incorporated

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑